The consumers who use GLP-1s may be more willing to try new products, they added, and those CPG items marketed as high protein, high fiber, nutrient added and GLP-1 friendly are currently selling well
Taste alterations, including bad taste in the mouth, are not listed among the common adverse reactions (occurring in 5% of patients) in the FDA-approved prescribing information for semaglutide products
GLP-1 agonism: Reduces appetite, slows gastric emptying, promotes satiety GIP agonism: Enhances insulin secretion, may reduce GLP-1-related nausea Glucagon agonism: Increases hepatic glucose output control, drives thermogenesis and energy expenditure Phase 2 clinical trial data published in 2023 showed subjects lost an average of 24.2% of body weight over 48 weeks making it arguably the most potent weight-loss compound currently known
Vomiting occurs less frequently than nausea but can be problematic when it does occur, particularly if it leads to dehydration or interferes with nutrition and medication absorption
Conclusion Telehealth prescribing of GLP-1 medications is transforming diabetes care by expanding access and convenience